Locations:
Min Investment:
Max Investment:
Target Investment:
(2019 - 2019)
(2010 - 2010)
CME credits
(2010 - 2010)
(2009 - 2009)
Certificate of Advanced Studies
(2003 - 2004)
2022
2021 - 2022
2021 - 2022
2015 - 2021
2015 - 2021
LimmaTech Biologics is a biotech Company based on innovative platform to make bioconjugate. Former GlycoVaxyn, acquired by GSK in 2015, LimmaTech maintains a close relationship with GSK for the development of novel vaccines . Moreover, with the deep in-house expertise of glycoconjugation is also working in the therapeutic field.
2009 - 2015
2012 - 2015
• Overall responsibility for designing and managing company’s drug development strategy and operations •Assessed and evaluated the early stage product portfolio, streamlined preclinical development and prioritised clinical development •Built and developed an effective operational clinical team, created partnerships with relevant academic institutions. Selected participants, built agenda and managed the meetings of the International Advisory Board, international Expert- and Investigator’s groups •Responsible for the regulatory submission process (IND/IMPD submission to FDA/EMEA and Swissmedic)
2011 - 2012
2009 - 2011
2007 - 2009
2007 - 2009
Design, Initiate and Conduct pre and post-market studies in Europe and US for medical device.
2006 - 2007
2006 - 2007
2001 - 2005
2001 - 2005